.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Chubb
McKinsey
Novartis
Julphar
Accenture
Harvard Business School
Cerilliant
Baxter

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,889,159

« Back to Dashboard

Which drugs does patent 8,889,159 protect, and when does it expire?


Patent 8,889,159 protects HARVONI, EPCLUSA, and SOVALDI, and is included in three NDAs.

This patent has sixty-seven patent family members in twenty-eight countries.

Summary for Patent: 8,889,159

Title:Compositions and methods for treating hepatitis C virus
Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
Inventor(s): Cleary; Darryl G. (Chapel Hill, NC), Reynolds; Charles J. (Greenville, NC), Berrey; Miriam Michelle (Durham, NC), Hindes; Robert G. (Skillman, NJ), Symonds; William T. (San Francisco, CA), Ray; Adrian S. (Redwood City, CA), Mo; Hongmei (Palo Alto, CA), Hebner; Christy M. (Belmont, CA), Oliyai; Reza (Burlingame, CA), Zia; Vahid (San Carlos, CA), Stefanidis; Dimitrios (Mountain View, CA), Pakdaman; Rowchanak (San Carlos, CA), Casteel; Melissa Jean (Burlingame, CA)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:13/686,664
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Gilead Sciences Inc
HARVONI
ledipasvir; sofosbuvir
TABLET;ORAL205834-001Oct 10, 2014RXYesYes8,889,159► SubscribeY FOR THE TREATMENT OF HEPATITIS C
Gilead Sciences Inc
EPCLUSA
sofosbuvir; velpatasvir
TABLET;ORAL208341-001Jun 28, 2016RXYesYes8,889,159► SubscribeY FOR THE TREATMENT OF HEPATITIS C
Gilead Sciences Inc
SOVALDI
sofosbuvir
TABLET;ORAL204671-001Dec 6, 2013RXYesYes8,889,159► SubscribeY FOR THE TREATMENT OF HEPATITIS C
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,889,159

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,393,256Methods for treating HCV► Subscribe
9,549,941Compositions and methods for treating hepatitis C virus► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,889,159

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel232889► Subscribe
Japan2014533733► Subscribe
Japan5899327► Subscribe
Japan2014526516► Subscribe
Japan6073897► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
UBS
Colorcon
Daiichi Sankyo
Johnson and Johnson
Fish and Richardson
Dow
Federal Trade Commission
Chinese Patent Office
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot